Chimeric antigen receptor T cell (CAR-T) therapy has indisputably become one of the industry’s hottest topics and the next 18 months could see the first CAR-T drugs filed for US approval. But behind the excitement for all things CAR-T lie a number of obstacles in their path to approval.

In its second deep-dive into the CAR-T space EP Vantage explores how much of an advantage it will be for to be the first company to achieve approval in a market that has never been tested and the ability to charge premium pricing can only be guessed at.

In this comprehensive report EP Vantage also examines:

The complexity and expense of manufacturing

The poor durability of many current CAR constructs

The growing ways by which tumour cells can become resistant to CAR-T therapy

The fear of severe toxicities

The cost and reimbursement questions surrounding CAR-T treatments

报告下载：

CAR-T研发现状